1stOncology™: Cancer Intelligence Service – Page 14639 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Nordic Nanovector Completes Patient Enrolment Into Phase 1 Trial of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL)

On July 11, 2019 Nordic Nanovector ASA (OSE: NANO) reported that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation (Press release, Nordic Nanovector, JUL 11, 2019, View Source [SID1234537494]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation study designed to assess the safety, tolerability, pharmacokinetic profile and preliminary anti-tumour activity of a single administration of Betalutin. Patients were enrolled at clinical trial sites in the US and Europe. More information on this study can be found at www.clinicaltrials.gov (NCT02658968). Preliminary results are expected in the second half of 2019.

DLBCL is an aggressive form of non-Hodgkin’s Lymphoma (NHL) that accounts for up to 43% of all NHL cases, making it the most common form of the disease. Approximately 40% of DLBCL patients relapse after first-line combination treatment with rituximab and chemotherapy and only 30-40% of relapsed patients respond with subsequent high-dose chemotherapy followed by Stem Cell Transplantation (ref. 1 below). There are currently very few therapeutic options for patients not eligible for SCT, which makes relapsed DLBCL a serious unmet medical need. The number of diagnosed cases of DLBCL in the US and Europe in 2016 was 26,500 and 17,200, respectively. These numbers are expected to reach 31,500 (US) and 19,000 (Europe) by 2024 (ref. 2 below).

Lisa Rojkjaer, Chief Medical Officer at Nordic Nanovector, said: "We are delighted to have reached this important milestone and look forward to the preliminary results during the second half of the year. Planning is underway for an expansion cohort to further assess safety and efficacy in this challenging to treat patient population. We expect more patients to be enrolled when the best dose is selected from the first part of the study."

References

1. L.S. Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse large B cell lymphoma (2014) South Asian J. Cancer 3(1): 66–70

2. Non-Hodgkin’s Lymphoma (2015) Decision Resources

Luminex Corporation Second Quarter Earnings Release Scheduled for July 31, 2019

On July 11, 2019 Luminex Corporation (NASDAQ: LMNX) reported that it plans to report results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019 (Press release, Luminex, JUL 11, 2019, View Source [SID1234537493]). A press release announcing the results is scheduled for release after the close of trading on that date.

Management will hold a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2019 on July 31, 2019, at 4:30 p.m. Eastern time.

The conference call will be webcast live and may be accessed at Luminex Corporation’s website at View Source Simply log on to the website, go to the About Luminex section and access the Investor Relations link. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the ‘replay’ link.

AMN Healthcare to Host Second Quarter 2019 Earnings Conference Call on Tuesday, August 6, 2019

On July 11, 2019 AMN Healthcare Services, Inc. (NYSE: AMN), healthcare’s leader and innovator in workforce solutions and staffing services, reported that it will host a conference call to discuss its second quarter 2019 financial results on Tuesday, August 6, 2019 at 5:00 p.m. Eastern Time (Press release, AMN Healthcare Services, JUL 11, 2019, View Source [SID1234537492]). The Company also expects to issue an earnings news release on Tuesday, August 6, 2019 after market close at approximately 4:15 p.m. Eastern Time.

A live webcast of the call can be accessed through AMN Healthcare’s website at View Source Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Interested parties may participate live via telephone by dialing (800) 230-1092 in the U.S. or (612) 288-0329 for international callers. Following the conclusion of the call, a replay of the webcast will be available at the Company’s website. Alternatively, a telephonic replay of the call will be available beginning at 7:30 p.m. Eastern Time on August 6, 2019, and can be accessed until 11:59 p.m. Eastern Time on August 20, 2019 by calling (800) 475-6701 in the U.S. or (320) 365-3844 internationally, with access code 469775.

Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite

On July 11, 2019 Gilead Sciences, Inc. (NASDAQ: GILD) reported that Christi L. Shaw will join the company as Chief Executive Officer of Kite, a Gilead Company, and will become a member of Gilead’s senior leadership team (Press release, Gilead Sciences, JUL 11, 2019, View Source [SID1234537491]).

Ms. Shaw is a renowned leader with deep experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry. Ms. Shaw currently serves as Senior Vice President of Eli Lilly &. Co., and President of Lilly Bio-Medicines. She also serves as a board member of both Avantor, Inc. and the Biotechnology Industry Organization (BIO), and as an advisor to the Healthcare Businesswomen’s Association.

Prior to joining Lilly, Ms. Shaw most recently served as U.S. Country Head and President of Novartis Corp. and North American Head of Novartis Oncology. She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin.

"We conducted an extensive search for a new leader at Kite and we believe that Christi’s unique set of skills will allow us to continue to build on our leadership position in cell therapy," said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. "Christi’s vast experience across complex therapeutic areas, and particularly in oncology, will serve Kite very well. She is clearly a leader who will bring teams and individuals together and I am confident she will build upon the entrepreneurial spirit at Kite as we seek to help more people with cancer around the world."

"Kite’s vision of transformational drug development – and of curing cancer – is one that I am extremely passionate about," said Ms. Shaw. "I look forward to working with the many talented individuals in this organization, as we change the way cancer is treated and bring forward important, life-saving therapies."

CURE Media Group Adds the Healing NET Foundation to Its Strategic Alliance Partnership Program

On July 11, 2019 CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted solely to cancer updates and research, reported the addition of the Healing NET Foundation to its Strategic Alliance Partnership (SAP) program (Press release, CURE, JUL 11, 2019, View Source [SID1234537490]).

"We are excited to be partnering with the Healing NET Foundation," said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of CURE Media Group. "This foundation is helping patients across the nation with neuroendocrine cancer by bringing together multiple stakeholders."

The Healing NET Foundation is a nonprofit that strives to optimize the care of those with neuroendocrine cancer through the education of and collaboration among physicians, health care providers, patients and caregivers. Neuroendocrine tumors (NETs) are an unusual set of malignancies that are difficult to diagnose and cause many unusual symptoms that often lead to an improper or significantly delayed diagnosis. The Healing NET’s focus is advocating for a new standard of care that patients with NETs deserve.

"Collaboration is a core value of the Healing NET Foundation as we seek to foster a better understanding of neuroendocrine (NET) cancer in the medical communities and help patients connect with their physicians in ways that achieve top care. CURE Media Group and their Strategic Alliance Partnership aligns perfectly with our values and we are delighted to work with them to create more awareness and education about NET cancer," said Cindy Lovelace, co-founder and executive director of the Healing NET Foundation.

The SAP program builds a community of advocacy groups, medical associations and medical institutions to foster collaboration and an open exchange of information among trusted peers for the ultimate benefit of patients and their families. As part of this joint effort, CURE Media Group will work with the Healing NET Foundation to get the word out about NET cancers. Cure recently covered the Healing NET’s 2019 Summit in Nashville, Tennessee.

For more information about CURE Media Group’s SAP program, click here.

For more information about the Healing NET Foundation, click here.

About CURE Media Group

CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry-leading website, CUREtoday.com; innovative video programs, such as "CURE Connections"; a series of widely attended live events; and CURE magazine, which reaches over 1 million readers, as well as the dynamic website for oncology nurses, OncNursingNews.com, and its companion publication, Oncology Nursing News. CURE Media Group is part of the Cranbury, New Jersey-based MJH Associates, Inc., family of businesses, which includes the acclaimed OncLive platform of resources for the practicing oncologist. For more information, visit View Source and View Source